By Fineline Cube 
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly known as BeiGene, Ltd., reported exceptional first-quarter 2026 financial results, with total revenues reaching USD 1.513 billion, representing a 35% year-over-year (YOY) increase. The company’s product sales totaled USD 1.487 billion, up 34% YOY, while adjusted net profits skyrocketed 175% YOY to USD 375 million.
Financial Highlights – Q1 2026
| Metric | Q1 2026 | YOY Change | Notes |
|---|---|---|---|
| Total Revenues | USD 1.513 billion | +35% | Driven by strong product portfolio performance |
| Product Sales | USD 1.487 billion | +34% | Core oncology products leading growth |
| Adjusted Net Profit | USD 375 million | +175% | Significant margin expansion and operational leverage |
| 2026 Full-Year Guidance | USD 6.3–6.5 billion | Upgraded | Reflects strong market momentum and execution |
Product Portfolio Performance
Core Oncology Franchise
- Brukinsa (zanubrutinib) – BTK inhibitor: USD 1.1 billion in Q1 2026 sales (+38% YOY), crossing the critical $1 billion quarterly milestone
- Tevimbra (tislelizumab) – PD-1 inhibitor: USD 206 million in Q1 2026 sales (+20% YOY), maintaining strong growth trajectory
Strategic Partnerships
- Amgen-Licensed Products: USD 142 million in Q1 2026 sales (+25% YOY), demonstrating successful commercialization of partnered assets
The continued rapid uptake of core products reflects BeOne’s expanding global commercial footprint and increasing physician adoption across key oncology indications.
Market Impact & Strategic Outlook
- Global Oncology Leadership: With Brukinsa achieving $1.1 billion in quarterly sales, BeOne has established itself as a major player in the global BTK inhibitor market, competing effectively against established competitors.
- Diversified Growth Engine: The combination of proprietary assets (Brukinsa, Tevimbra) and strategic partnerships (Amgen) creates a balanced revenue stream with multiple growth vectors.
- Profitability Inflection: The 175% YOY increase in adjusted net profits signals successful transition from investment phase to profitability, driven by operating leverage and margin expansion.
- Guidance Upgrade: The revised 2026 revenue guidance of USD 6.3–6.5 billion represents significant upward revision, reflecting management confidence in sustained momentum across the portfolio.
BeOne’s strong Q1 performance validates its strategy of building a globally competitive oncology franchise through both internal innovation and strategic partnerships, positioning the company for continued leadership in the rapidly evolving cancer therapeutics landscape.
Forward‑Looking Statements
This brief contains forward-looking statements regarding financial performance, product sales, and revenue guidance. Actual results may differ due to risks including market competition, regulatory changes, and global economic conditions.-Fineline Info & Tech